
    
      This is a Phase 2 study of SPR001 for the treatment of classic CAH that will provide 12 weeks
      of open-label treatment to eligible subjects. To be eligible for this study, an individual
      must either have completed Study SPR001-201 or meet eligibility criteria for SPR001-naïve
      subjects. The expected duration of study participation for each subject is up to
      approximately 5 months. This includes a screening period of ≤30 days, a treatment period of
      12 weeks, and a safety follow-up period of 30 days.
    
  